Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news.

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted therapies, cell therapy enhancements and next generation CAR-T therapies.

Encouraging progress through clinical trials of Prescient’s foundational assets PTX-100 and PTX-200 (with the PTX-100 trial progressing to expansion cohort last week following successful Phase 1b) and CAR-T safety and manufacturing milestone with OmniCAR.

We gave Steven Yatomi-Clarke, CEO of Prescient Therapeutics, 90 seconds to tell us more about the recent announcement.

Have a good idea for our next 90 Seconds With segment? Email us at [email protected]